

# Partnering for Success

## Company Highlights

- **Privately held company founded in 2018**
- **Locations in Florida, North Carolina and Connecticut**
- **Commercial manufacturing partnerships in the US/EU**
- **40 issued patents, 48 pending patents**

## Market Trends

- **Vials**  
Global injectable market for vials is expected to reach 17 billion units in 2026<sup>1</sup>
- **Prefilled Syringes**  
Global injectable market for pre-filled syringes is expected to reach 7 billion units in 2026<sup>2</sup>
- **Prefilled, subcutaneous (SC)**  
Drug administration units expected to grow annually at 13.5%<sup>2</sup>
- **Vaccines**  
Will comprise ~70% of the pre-filled, injectable market over the next 5 years<sup>2</sup>
- **Monoclonal Antibodies**  
Expected to reach 7.6B units in 2026 with 7.4% CAGR<sup>1</sup>

<sup>1</sup> Zion Market Research Report: Sterile Fill Finish Injectable: Global & Regional Market Size, Historical Trends and Forecasts 2016 – 2026


<sup>2</sup> Zion Market Research Report: Prefilled Injectable: Global & Regional Market Size, Historical Trends and Forecasts 2016-2026.

## APIJECT TECHNOLOGY — REDEFINING INJECTABLE DRUG DELIVERY

At ApiJect, our experts design proprietary injection systems that allow partners to deliver their drug products using cost-effective Blow-Fill-Seal (BFS) manufacturing technology. Our first designed device is the Prefilled ApiJect Injector\*: a proprietary, sterile, unit-dose injection system that is market differentiated, commercially scalable, and provides the safety, convenience, and time savings of a prefilled format to the end user.

The standard design can be seen in the figure below, which illustrates two primary components: a BFS container (low-density polyethylene) with the drug product and an attachable needle hub with needle shield.

### Prefilled ApiJect Injector System\*



## A PLATFORM TO PROVIDE DRUG DELIVERY SOLUTIONS

As parenterals continue to grow, more companies are looking for solutions that deliver the benefits of prefilled formats but with the manufacturing efficiencies of glass filling. That is why we created the ApiJect Platform: a design and manufacturing process that merges BFS and plastic components to create single-dose, prefilled parenterals customized for your drug product.

While a 0.5mL Prefilled ApiJect Injector\*, was created for vaccines and other smaller-dose products, the ApiJect Platform is designed to serve a very wide range of parenterals for all markets. Our scope includes all major injection routes of intramuscular, subcutaneous, intradermal and intravenous, as well as traditional BFS routes of oral, otic, optic, and inhalation. In addition, BFS can handle a wide range of fill volumes, including injectable doses of 0.25-5.0mL.

\* The Prefilled ApiJect Injector has not been cleared by the FDA or other regulatory authorities.

## EXPANDING BFS FOR INJECTABLES

Over the last 20 years, BFS engineers have made strong improvements that allow BFS to serve a wider range of sterile liquid pharmaceuticals. ApiJect experts have advanced this process much further with our **temperature management technology**. This proprietary process enables BFS to potentially serve a wide range of heat-labile injectables, including biologics, in addition to emulsions, suspensions, and other challenging formulations.

## MARKET CONSIDERATIONS

With the intense global growth of sterile injectables over the next ten years, it is the right time to reconsider the best process to meet the increased demand of the medical community and patients.

**BFS offers several advantages to manufacturers, including:**

- Advanced aseptic process
- High-speed fill rates
- Low cost of goods
- Primary package comprised of one raw material
- Efficient production processes

In addition, the flexibility of BFS output enables a single line to produce up to 25,000 units of drug product per hour.

## DESIGN, PROTOTYPING, & TESTING

At the Technology and Development Center, our device and BFS experts leverage the ApiJect Platform to design the right drug delivery system for your drug product.

**Our services include:**

- BFS process evaluation
- Drug product compatibility testing
- Device testing
- Prototype BFS mold design and creation
- Device design and prototype manufacturing
- Secondary packaging development



Rommelag® Bottelpack 460

## APIJECT AS YOUR PREFERRED PARTNER

ApiJect continues to invest in R&D to develop innovative ways of enhancing device performance for the best patient experience as well as a focus on modular BFS manufacturing to simplify commercial technology transfer.

Whether you have a branded or generic pharmaceutical product, ApiJect has flexible arrangements to work with your team from select development services to full-scale commercial production through our growing partner network in the United States and Europe.

As a first step, speak with our business leaders about conducting a feasibility study with your drug product.

## MEET OUR TEAM

To learn more about how we are working with BFS to create prefilled syringes and other drug delivery systems for a wide range of sterile liquids, contact [sales@apiject.com](mailto:sales@apiject.com).



**Kevin Ostrander**  
Vice President,  
Business  
Development



**Cindy Benedict**  
Executive Director,  
Business  
Development



**Bo Kowalczyk**  
Sr. Vice President,  
Commercial  
Development

### FOR MORE INFORMATION:

Company:  
visit [www.apiject.com](http://www.apiject.com)



Blow-Fill-Seal:  
visit [apiject.com/publications](http://apiject.com/publications)

Manufacturing:  
visit [apiject.com/publications](http://apiject.com/publications)

ApiJect Systems, Corp.  
2 High Ridge Park, Stamford, CT 06905  
Phone: (203) 998-6176  
Email: [sales@apiject.com](mailto:sales@apiject.com)

©2022 ApiJect Systems, Corp. All rights reserved.